Articles tagged with Cho Cells
Researchers developed a machine learning model that accounts for biological variability to identify optimal formulations for serum-free culture media. The model achieved approximately 1.6-fold higher cell density compared to commercially available products.
A new strategy enhances pharmaceutical production in Chinese hamster ovary cells by knocking out a gene circuit responsible for producing lactic acid. The approach improves growth rates and significantly increases protein yield, overcoming a decades-old challenge in biomanufacturing.
Researchers from Tokyo University of Science discovered that manipulating polyamines enhances the functional profiles of monoclonal antibodies. The study found that controlling polyamine levels increases IgG galactosylation, leading to improved therapeutic efficacy.
Researchers have developed a genome-editing technique that can eliminate up to 70% of contaminating proteins in recombinant-protein drugs, making them cheaper and purer. The technology uses CRISPR-Cas mediated gene editing to reduce purification demands and improve drug quality.
Researchers from the Technical University of Denmark have discovered a way to improve EPO production by knocking out specific genes in Chinese Hamster Ovary cells. This results in a 1.4-fold increase in production and significantly improved product quality, with up to 40% of the most active EPO form produced.
Researchers have successfully produced mammalian cell lines that can produce human glycosylation profiles for Alpha-1-antitrypsin proteins. This breakthrough enables the production of recombinant Alpha-1-antitrypsin without dependency on human donors, reducing treatment costs and improving patient outcomes.
A team led by Clemson University's Sarah Harcum aims to improve the stability of Chinese hamster ovary cells used to manufacture biopharmaceuticals, which could lead to lower drug prices and increased patient access to expensive medicines.
A new computational model describes the metabolism of Chinese hamster ovary cells (CHO), enabling comprehensive simulations to optimize protein production. The iCHO1766 model has been tested with high accuracy, promising to reduce the cost and increase the availability of biotherapeutic proteins.
The CHO-K1 genome provides a better understanding of the genetics of CHO cells, accelerating the discovery and development of new recombinant protein therapies. The study identified homologs to 99% of human glycosylation-associated genes in the CHO-K1 genome.
Researchers at Lawrence Berkeley National Laboratory demonstrate a novel approach to assemble cells into three-dimensional, multicellular microtissues. By controlling cellular connections, they can create tissues with sophisticated properties, such as the stem-cell niche.
Researchers developed a secretory Apoptin fusion protein that induces apoptosis in hepatocellular carcinoma HepG2 cells, offering new potential for cancer gene therapy. The study's findings suggest the therapeutic usage of Apoptin may be increased with its secretory characteristic.
Research has established Neowater's ability to refine the standard hybridoma production process, leading to enhanced yields of human monoclonal antibodies. The novel nanoparticle-doped water also stimulates new membrane formation, improving cell growth and proliferation rates.